More tools:Markets·Screener·Research·Chat

Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares (CANF) Financial Statements

Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares
SIC 8733
FIGI BBG003CMFFC8
XASE · usd
2.29▲ 0.06 (2.69%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close2.23
Day's Range2.25 – 2.31
52-Week Range0.17 – 10.40
Volume163.0K
Avg Volume718.4K
Share Statistics
Shares Outstanding
Employees5
ExchangeXASE
Listed2012-09-10
Share count as of December 31, 2025
Loading Income Statement…
Key questions about Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Market Cap?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Market Cap is $6.0M, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Enterprise Value?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Enterprise Value is -$459.8K, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Price / Sales?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Price / Sales is 10.7×, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EV / Revenue?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EV / EBITDA?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EV / EBITDA is 0.1×, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Revenue (TTM)?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Revenue (TTM) is $560.0K, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Net Income (TTM)?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Net Income (TTM) is -$8.8M, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EBITDA?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EBITDA is -$8.9M, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Diluted EPS (TTM)?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Diluted EPS (TTM) is -3.36, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EBITDA Margin?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EBITDA Margin is -1594.1%, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Revenues
YoY growth-39.9%
Research and development expenses
General and administrative expenses
Total operating expenses
% of revenue-2556.8%
Operating loss
% of revenue-2456.8%
Total financial income, net
Loss before taxes on income, Amount
Net loss
% of revenue-2426.7%
Basic net loss per share (in Dollars per share)
Diluted net loss per share (in Dollars per share)